Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib + Atezolizumab + Bevacizumab in Advanced Cholangiocarcinoma
NCT06439485Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2024
- Primary completion
- Feb 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib in cholangiocarcinoma (CCA), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2024; status: recruiting.
02
Drugs
pemigatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06439485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439485.